High-performance materials for advanced biologics administration
Covestro partners with Savicred to advance drug delivery solutions
- Meeting growing demands in biologics delivery
- Material solutions enable reliable delivery of high-volume biologics
- Enhanced performance supports patient self-administration at home
PITTSBURGH, June 24, 2025 – Covestro, a global leader in high-performance medical materials, is advancing the future of biologics delivery through its collaboration with Savicred Biotechnology Co., Ltd., a leading Chinese drug delivery device manufacturer. This month, Savicred unveiled a next-generation 2.25ml auto-injector enabled by material solutions from Covestro, designed to meet the growing global demand for high-volume, patient-friendly biologics delivery systems.
“The biologics delivery space presents tremendous opportunities for innovation as the industry moves toward more complex drug formulations and patient-friendly delivery systems,” said Nan Hu, Global Vice President, Sales & Market Development Healthcare, Engineering Plastics Business Entity of Covestro. "As a leading provider of high-performance medical materials, we enable drug delivery device manufacturers to develop more advanced, reliable solutions that ultimately improve the treatment experience for patients.”
The shift toward high-volume biologics delivery, driven by demands for reduced injection frequency and enhanced home treatment options, presents complex material science challenges. These devices must manage higher internal pressures and more viscous drug formulations while maintaining precise performance throughout their lifecycle. This requires materials that can deliver exceptional mechanical strength for structural integrity, dimensional stability for consistent dosing, and proven biocompatibility for patient safety—all while supporting efficient, scalable manufacturing processes.
Covestro's material technologies, developed through its global innovation network including key research facilities in the United States, are engineered to address these demanding requirements. The medical-grade Makrolon® polycarbonates combine high mechanical strength for reliable delivery of larger volumes with outstanding dimensional stability that ensures precise component fit and reliable performance in various storage and usage conditions. These materials also offer proven biocompatibility for patient safety, while their superior processability enables high-precision molding for complex device components. This comprehensive performance profile enables device manufacturers to scale up innovation confidently while maintaining safety and reliability.
“With the support of Covestro‘s innovative materials, Savicred has developed a 2.25ml auto-injector specifically designed for China’s rapidly evolving biologics market, offering pharmaceutical companies an effective platform for self-administration therapies,” said Xiao Lin, CEO at Savicred. “As we push the frontiers of biologics delivery, material choice is pivotal. Covestro‘s solutions provide the durability, consistency, and safety we need to develop devices that offer patients more convenient home treatment solutions and enhance their quality of life.”
About Savicred:
Savicred is driven by innovation, committed to providing high quality drug delivery systems, and dedicated to being a reliable partner of pharmaceutical companies globally. Savicred specializes in drug delivery systems R&D, manufacturing, and commercialization, providing total solutions for drug companies.
About Covestro:
Covestro is one of the world’s leading manufacturers of high-quality polymer materials and their components. With its innovative products, processes and methods, the company helps enhance sustainability and the quality of life in many areas. Covestro supplies customers around the world in key industries such as mobility, building and living, as well as the electrical and electronics sector. In addition, polymers from Covestro are also used in sectors such as sports and leisure, telecommunications and health, as well as in the chemical industry itself.
The company is geared completely to the circular economy. In addition, Covestro aims to achieve climate neutrality for its Scope 1 and Scope 2 emissions by 2035, and the Group’s Scope 3 emissions are also set to be climate neutral by 2050. Covestro generated sales of EUR 14.2 billion in fiscal year 2024. At the end of 2024, the company had 46 production sites worldwide and employed approximately 17,500 people (calculated as full-time equivalents).
Forward-Looking Statements
This news release may contain forward-looking statements based on current assumptions and forecasts made by Covestro AG. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Covestro’s public reports which are available at www.covestro.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.